Moreover, preplanned analyses from the FAST trial showed that higher levels of expression of CLDN18 (≥2+ in ≥70% of tumor cells) achieved a greater treatment advantage of zolbetuximab than lower levels. The gene discussed is CLDN18; the disease is neoplasm.